Position in NVS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
7 quarters on record
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Derivatives in NVS
reported options exposure · as of Jun 30, 2026CallValue
$39,963
CallShares
255
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Raiffeisen Bank International AG holds $427,125,963 across 9 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
129,513 | $155,341,789 | |
| 2 | ABBV |
AbbVie Inc.
|
379,931 | $95,605,836 | |
| 3 | MRK |
Merck & Co., Inc.
|
397,662 | $51,099,567 | |
| 4 | PFE |
Pfizer Inc
|
1,398,194 | $33,668,510 | |
| 5 | AMGN |
Amgen Inc
|
74,462 | $26,964,179 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
198,926 | $25,132,310 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
432,969 | $24,947,673 | |
| 8 | JNJ |
Johnson & Johnson
|
56,470 | $14,341,685 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $39,963 | 255 | Call | Sole | 2026-08-03 | |
| 2026-03-31 | $38,951 | 255 | Call | Sole | 2026-04-24 | |
| 2025-12-31 | $35,156 | 255 | Call | Sole | 2026-02-12 | |
| 2025-09-30 | $32,701 | 255 | Call | Sole | 2025-11-10 | |
| 2025-06-30 | $30,857 | 255 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $28,427 | 255 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $24,814 | 255 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||